Physician profile
Benjamin Swanson
NPI 1528564135
$1,768.06
in general payments reported to CMS, 2019-2025
21 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.51 · 2022: $607 · 2023: $392 · 2024: $367 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $252.83 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $228.60 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $180.71 | 2022-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $155.61 | 2022-2025 | Pifeltro, Delstrigo, Verquvo |
| Novo Nordisk INC | $134.23 | 2022-2025 | Rybelsus, Ozempic |
| Viiv Healthcare Company | $120.66 | 2024-2025 | Dovato, Cabenuva |
| Theratechnologies INC. | $112.11 | 2022-2023 | Egrifta, Trogarzo |
| Exact Sciences Corporation | $102.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.88 | 2024-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $80.58 | 2022-2025 | |
| Dexcom, INC. | $50.44 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.37 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $41.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.31 | 2022 | |
| Corcept Therapeutics | $34.09 | 2025 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.44 | 2022 | |
| Gilead Sciences, INC. | $20.18 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.86 | 2024 | Caplyta |
| Karl Storz Endoscopy-America | $17.51 | 2020 | |
| Janssen Biotech, INC. | $15.86 | 2022 | |
| Shield Therapeutics INC | $14.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.